Merck’s Endometrial Cancer ADC Phase 3 Trial Meets Survival Endpoints, Offering New Clues for Later-Line Treatment

Merck said its investigational antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) met the two primary endpoints of overall survival and progression-free survival in the Phase 3 TroFuse-005 clinical trial. The trial enrolled patients with advanced or recurrent endometrial cancer whose disease had worsened after platinum-containing chemotherapy and immunotherapy.

The key point of this result is not only tumor shrinkage or delayed progression, but the trial’s claim that survival-related benefit was observed. For patients who continue to progress after standard frontline treatment, subsequent options are usually limited, so any therapy that can improve survival in a randomized Phase 3 trial will draw attention from clinicians and regulators.

Sac-TMT is an antibody-drug conjugate (ADC). These drugs use antibodies to recognize tumor-associated targets and then deliver cytotoxic drugs into or near cancer cells, with the goal of increasing antitumor effects while reducing broad damage to normal tissue. However, ADCs are not equivalent to low-toxicity treatments, and their safety still depends on the target, linker, payload type, and patient condition.

According to currently disclosed information, TroFuse-005 enrolled 776 patients, with the control group receiving chemotherapy chosen by physicians. Merck said sac-TMT showed statistically significant improvement versus chemotherapy in both overall survival and progression-free survival, and also met secondary measures such as tumor response rate; safety was described as broadly consistent with existing studies and manageable.

It should still be noted that the press release and media reports have not yet provided specific survival months, hazard ratios, results in different subgroups, discontinuation rates, or details of serious adverse events. This information will affect how outsiders judge whether the magnitude of efficacy is sufficient to change clinical practice, and it will also affect how physicians assess the risks and benefits for different patients.

Endometrial cancer is one of the common gynecologic cancers, and treatment is more difficult after it becomes advanced or recurrent. If subsequent full data support the conclusions announced so far, sac-TMT may become an important candidate therapy after platinum-containing chemotherapy and immunotherapy; however, before formal approval and inclusion in treatment guidelines, full data publication and regulatory review are still needed.